Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2016

View Archived Issues

Yisheng Biopharma to collaborate with The Scripps Research Institute in developing new AIDS vaccine

Novel benzoselenazole derivatives as PET tracers for non-invasive assessment of Abeta plaques

S100A8/A9 is a potent serum and molecular imaging biomarker in seronegative arthritis

Ocular Therapeutix reports positive results for phase III trial of Dextenza

Capsazepine improves impaired lung mechanics during endotoxemia

FDA grants orphan and fast track designations to ARMO BioSciences' AM-0010

FDA transfers EUA for ReEBOV Ebola Antigen Rapid Test to Zalgen

Pfizer enters CRADA with NCI to evaluate three immunotherapy agents

EMA's CHMP recommends granting marketing authorization to Afstyla

OpGen collaborates with Merck & Co. on rapid diagnostics to tackle antibiotic resistance

Genfit initiates pediatric program for elafibranor in NAFLD/NASH

Texas A&M University patents antimycobacterial agents

Repros reports promising topline data from phase II studies of Proellex for uterine fibroids

Katholieke Universiteit Leuven discloses PMDT nucleoside phosphonates

FDA issues complete response letter for Heplisav-B BLA

Xiamen University describes ALK and/or c-Met inhibitors

Novartis develops FXR agonists

FDA awards orphan drug designation to ECCS-50 for scleroderma

Vallaurix presents MC1 receptor agonists

Seizure-induced glial activation in the hippocampus suppressed by the novel NAAA inhibitor ARN-16186

Novel delta opioid receptor agonist NC-2800 shows high anxiolytic and antidepressant activity

ERYTECH Pharma withdraws Graspa MAA in Europe

Reata Pharmaceuticals announces plans to study bardoxolone methyl in new indication

Sanofi Genzyme opts in to expand rights to codevelop, co-commercialize Alnylam's fitusiran

Pantoprazole decreases phlebotomy need in HFE-related hemochromatosis

Acticor Biotech and Mediolanum Farmaceutici enter agreement regarding ACT-017 for stroke

CHMP supports approval of AbbVie's Humira for adolescents with hidradenitis suppurativa

Midostaurin NDA granted priority review by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...